KR102919967B1 - 신경 가소성을 유도하기 위한 방법 및 조성물 - Google Patents

신경 가소성을 유도하기 위한 방법 및 조성물

Info

Publication number
KR102919967B1
KR102919967B1 KR1020217009271A KR20217009271A KR102919967B1 KR 102919967 B1 KR102919967 B1 KR 102919967B1 KR 1020217009271 A KR1020217009271 A KR 1020217009271A KR 20217009271 A KR20217009271 A KR 20217009271A KR 102919967 B1 KR102919967 B1 KR 102919967B1
Authority
KR
South Korea
Prior art keywords
delete delete
stroke
glu
amino acid
leu lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217009271A
Other languages
English (en)
Korean (ko)
Other versions
KR20210054542A (ko
Inventor
제리 실버
유 루오
푸쳉 루오
Original Assignee
케이스 웨스턴 리저브 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케이스 웨스턴 리저브 유니버시티 filed Critical 케이스 웨스턴 리저브 유니버시티
Publication of KR20210054542A publication Critical patent/KR20210054542A/ko
Application granted granted Critical
Publication of KR102919967B1 publication Critical patent/KR102919967B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020217009271A 2018-09-05 2019-08-29 신경 가소성을 유도하기 위한 방법 및 조성물 Active KR102919967B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727420P 2018-09-05 2018-09-05
US62/727,420 2018-09-05
PCT/US2019/048698 WO2020051051A1 (en) 2018-09-05 2019-08-29 Methods and compositions for inducing neural plasticity

Publications (2)

Publication Number Publication Date
KR20210054542A KR20210054542A (ko) 2021-05-13
KR102919967B1 true KR102919967B1 (ko) 2026-01-30

Family

ID=69722599

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009271A Active KR102919967B1 (ko) 2018-09-05 2019-08-29 신경 가소성을 유도하기 위한 방법 및 조성물

Country Status (8)

Country Link
US (2) US12138300B2 (https=)
EP (1) EP3846838A4 (https=)
JP (2) JP7589143B2 (https=)
KR (1) KR102919967B1 (https=)
CN (1) CN113260373B (https=)
AU (1) AU2019334965B2 (https=)
CA (1) CA3111512A1 (https=)
WO (1) WO2020051051A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途
WO2025169981A1 (ja) * 2024-02-07 2025-08-14 第一工業製薬株式会社 脳機能を改善するための環状ペプチド誘導体組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366949A1 (en) * 2012-04-09 2015-12-24 Case Western Reserve University Compositions and methods for inihibiting the activity of lar family phosphatases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945108A1 (de) 1979-11-08 1981-05-21 Interatom Internationale Atomreaktorbau Gmbh, 5060 Bergisch Gladbach Faltenbalgkompensator
FR2641360B1 (fr) 1988-12-29 1991-02-22 Commissariat Energie Atomique Compensateur de dilatation monte entre deux tuyauteries
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1995009656A1 (en) 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
WO2002083182A2 (en) 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
KR100999043B1 (ko) 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
WO2010129681A1 (en) 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2011022462A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
WO2012019086A2 (en) 2010-08-06 2012-02-09 The University Of North Carolina At Chapel Hill Inhibition of lar phosphatase to enhance therapeutic angiogenesis
US9744188B2 (en) 2011-02-18 2017-08-29 President And Fellows Of Harvard College Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
US20150084328A1 (en) 2013-09-24 2015-03-26 Witzenmann Gmbh Compensator arrangement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366949A1 (en) * 2012-04-09 2015-12-24 Case Western Reserve University Compositions and methods for inihibiting the activity of lar family phosphatases

Also Published As

Publication number Publication date
EP3846838A4 (en) 2022-06-08
EP3846838A1 (en) 2021-07-14
US12138300B2 (en) 2024-11-12
JP2024113090A (ja) 2024-08-21
WO2020051051A1 (en) 2020-03-12
CN113260373A (zh) 2021-08-13
US20250255939A1 (en) 2025-08-14
AU2019334965A1 (en) 2021-03-25
JP7589143B2 (ja) 2024-11-25
AU2019334965B2 (en) 2025-01-23
KR20210054542A (ko) 2021-05-13
CA3111512A1 (en) 2020-03-12
CN113260373B (zh) 2025-04-22
JP2021536461A (ja) 2021-12-27
US20210330757A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7829511B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
JP6401057B2 (ja) 虚血のための組み合わせ療法
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
JP2023537318A (ja) 中枢神経系障害の処置のためのキメラタンパク質および使用方法
CN113597304A (zh) 原发性中枢神经系统淋巴瘤的组合治疗
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
JP2017521408A (ja) 無毒性破傷風毒素ｃフラグメント（ｔｔｃ）を使用して筋量を増加させる方法
JP5784754B2 (ja) 神経疾患の予防または処置のためのｉｃａｍ−１の使用
US8629242B2 (en) Methods of inhibiting calcineurin with ApoE analogs
US20090291887A1 (en) Proteins of the SDF-1-Family for the Manufacturing of a Medicament
RU2575570C2 (ru) Применение нейрегулина для лечения повреждения периферических нервов
JP2001524944A (ja) 神経障害性疼痛の緩和方法
HK40002768B (en) Compositions for treating neural injury by inhibiting the activity of lar family phosphatases
Moss Effects of Heregulin on Muscle: A Biochemical and Histological Analysis
JP2008255071A (ja) 軸索伸長促進剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)